PHAR
Pharming Group

913
Mkt Cap
$1.1B
Volume
15,913.00
52W High
$17.76
52W Low
$7.31
PE Ratio
1,118.75
PHAR Fundamentals
Price
$16.44
Prev Close
$16.11
Open
$16.77
50D MA
$14.66
Beta
0.43
Avg. Volume
10,374.30
EPS (Annual)
-$0.1761
P/B
4.17
Loading...
Loading...
News
all
press releases
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Should You Buy?
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Still a Buy...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·5h ago
News Placeholder
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - What's Next?
Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - What's Next...
MarketBeat·6d ago
News Placeholder
Pharming Group (NASDAQ:PHAR) Shares Up 8.6% - Time to Buy?
Pharming Group (NASDAQ:PHAR) Trading 8.6% Higher - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's Why
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's Why...
MarketBeat·8d ago
News Placeholder
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
read more...
Benzinga·8d ago
News Placeholder
Pharming Group (NASDAQ:PHAR) Sets New 1-Year High - Here's What Happened
Pharming Group (NASDAQ:PHAR) Hits New 52-Week High - Here's Why...
MarketBeat·9d ago
News Placeholder
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks·10d ago
News Placeholder
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect?
The mean of analysts' price targets for Pharming Group (PHAR) points to a 100.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·10d ago
News Placeholder
FY2025 EPS Estimates for Pharming Group Raised by Analyst
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Pharming Group in a research report issued on Thursday...
MarketBeat·11d ago

Latest PHAR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.